![155493-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/155493-Thumbnail%20Image.png?versionId=uATcc9ygEmEwgmpyuaSmXPxzv.fgwTfv&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T032250Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=3ae417c891fd08c0f5dd04aa1a14dab2f3a2daebcf472b19c0fa9ca5d8111fbe&itok=auTbk-kT)
![156151-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/156151-Thumbnail%20Image.png?versionId=mVeEtMo_MB3joPzdtCS5z0kHeBHgG3F.&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T205530Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=340d96a456d335eda48ffb75952f1a0f7346766f31a547bc87722908d380b7e8&itok=udKyyF9W)
Alloying selenium into ReS2 in the creation of ReS2xSe2-x, tunes the band gap and changes its vibrational spectrum. Depositing this alloy using bottom up approach has resulted in the loss of crystallinity. This loss of crystallinity was evidenced by grain boundaries and point defect shown by TEM images.
Also, in the creation of TiS3xSe3-x, by alloying Se into TiS3, a fixed ratio of 8% selenium deposit into TiS3 host matrix is observed. This is despite the vastly differing precursor amounts and growth temperatures, as evinced by detailed TEM, EDAX, TEM diffraction, and Raman spectroscopy measurements. This unusual behavior contrasts with other well-known layered material systems such as MoSSe, WMoS2 where continuous alloying can be attained. Cluster expansion theory calculations suggest that only limited composition (x) can be achieved. Considering the fact that TiSe3 vdW crystals have not been synthesized in the past, these alloying rejections can be attributed to energetic instability in the ternary phase diagrams estimated by calculations performed. Overall findings highlight potential means and challenges in achieving stable alloying in promising direct gap and high carrier mobility TiS3 materials.
![128211-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/128211-Thumbnail%20Image.png?versionId=JabSez5qbrAg2f2dAyvLj0bpDgooR6gX&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T033248Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=eec0f77202f172e3359a31561c94929071d067a9d15f34dc049c8a3737224a9c&itok=GkbLrRBt)
We described the rapid production of the domain III (DIII) of the envelope (E) protein in plants as a vaccine candidate for West Nile Virus (WNV). Using various combinations of vector modules of a deconstructed viral vector expression system, DIII was produced in three subcellular compartments in leaves of Nicotiana benthamiana by transient expression. DIII expressed at much higher levels when targeted to the endoplasmic reticulum (ER) than that targeted to the chloroplast or the cytosol, with accumulation level up to 73 μg DIII per gram of leaf fresh weight within 4 days after infiltration. Plant ER-derived DIII was soluble and readily purified to > 95% homogeneity without the time-consuming process of denaturing and refolding. Further analysis revealed that plant-produced DIII was processed properly and demonstrated specific binding to an anti-DIII monoclonal antibody that recognizes a conformational epitope. Furthermore, subcutaneous immunization of mice with 5 and 25 μg of purified DIII elicited a potent systemic response. This study provided the proof of principle for rapidly producing immunogenic vaccine candidates against WNV in plants with low cost and scalability.
![128212-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/128212-Thumbnail%20Image.png?versionId=gvMGJaauKboeRnvTThiGB9uGG2A1KuPE&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T030123Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=21570380d861af2cbb48bcc7c93783661e02260cbdf41ceba85d240a894f7239&itok=H7Rh3hbk)
The increasing world demand for human biologics cannot be met by current production platforms based primarily on mammalian cell culture due to prohibitive cost and limited scalability [1]. Recent progress in plant expression vector development, downstream processing, and glycoengineering has established plants as a superior alternative to biologic production [2–4]. Plants not only offer the traditional advantages of proper eukaryotic protein modification, potential low cost, high scalability, and increased safety but also allow the production of biologics at unprecedented speed to control potential pandemics or with specific glycoforms for better efficacy or safety (biobetters) [5, 6]. The approval of the first plant-made biologic (PMB) by the United States Food and Drug Administration (FDA) for treating Gaucher’s disease heralds a new era for PMBs and sparks new innovations in this field [7, 8].
![135589-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/135589-Thumbnail%20Image.png?versionId=ERt7hjbI6lu2HKY6BGCPjBYkj80tm8u_&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T030123Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=65b1436f5eae00bda41102714cd62c32def6dffb0237e90bfd7a27eff72a60d8&itok=cZdyRX0H)
![135520-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/135520-Thumbnail%20Image.png?versionId=VCQwcZ9kaurdKdqugRw1uGmqhPoCbqZU&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T215301Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=823a45b9a532aea230df71a6774d69790022a9b34f6b559b3d263198e4ab3db1&itok=WhSARfcx)
![135540-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/135540-Thumbnail%20Image.png?versionId=hmCOfpkZHhW8GkJOOzU1PioCFwu5poSO&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T020405Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=9713adf0c6f4c6490564d229bb303291ab59d8e002413be6e1db3ea8bd402f5e&itok=ut5Dfi1f)
![131627-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/131627-Thumbnail%20Image.png?versionId=JHGy0Iw089bcPuFyYxrcjSWsx1JoyODM&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T181816Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=fcced35c300d214b4826c63f58b3c332a71ba618cb6afca5483ac728cc35774e&itok=ZvSJYXi6)
![133440-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/133440-Thumbnail%20Image.png?versionId=Qyx8Uoze1DFRXwsMWURsOQ_K2b7iTBuq&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T030123Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=b39a2293f362907ebce77eea9540e25cf0812ed1c07e9fafc74d7cbf5eb0a3b9&itok=jM4Khk3K)